Refoxy Pharmaceuticals
Refoxy Pharmaceuticals develops next-generation medicines targeting the FOXO3 transcription factor to treat age-related chronic conditions. The company's lead program focuses on Idiopathic Pulmonary Fibrosis (IPF), utilizing small molecules that have demonstrated anti-fibrotic effects in preclinical studies. Their broader pipeline aims to address fibrotic and cardiovascular diseases by enhancing cellular resilience and the body's response to stress.
Visit websiteCologne, Germany
Biotechnology
Pharmaceuticals
Healthcare
Longevity
Funding summary
- Total raised
- €9.1M
- Funding rounds
- 1
Investors in Refoxy Pharmaceuticals
Investors on record for Refoxy Pharmaceuticals. Click any investor to view their CAPLINK profile and funding criteria.
Fundraising for a startup like Refoxy Pharmaceuticals?
Explore CAPLINK's investor database of thousands of active VCs and angels.
Browse investors